Sarepta Therapeutics Inc (SRPT) Stock Analysis

Sarepta Therapeutics Inc (SRPT) is a publicly traded company in the HEALTHCARE sector. It trades at $16.25, carries a market capitalization of $1.86B, a price-to-earnings ratio of 50.31. This page summarizes the public market data, fundamentals, and frequently asked questions for SRPT, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Sarepta Therapeutics Inc currently has a Neutral sentiment score of -0.02.

About Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc. is a pioneering biopharmaceutical company based in Cambridge, Massachusetts, that focuses on the development of RNA-targeted and gene therapies for rare genetic disorders, particularly Duchenne muscular dystrophy (DMD). With an innovative pipeline and a strong commitment to addressing significant unmet medical needs, Sarepta is reshaping treatment paradigms in genetic medicine. The company's advanced scientific expertise and cutting-edge technologies position it as ...

GNG Research Analysis

GNG Research scores Sarepta Therapeutics Inc (SRPT) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SRPT.

Frequently Asked Questions

Does SRPT pay dividends?

Sarepta Therapeutics Inc (SRPT) does not currently pay a regular dividend.

What is SRPT's P/E ratio?

Sarepta Therapeutics Inc has a price-to-earnings (P/E) ratio of 50.31.

What is SRPT's market cap?

Sarepta Therapeutics Inc (SRPT) has a market capitalization of $1.86B with a current stock price of $16.25.